Swedish study: HPV vaccines protect against cervical cancer after 18 years
HPV vaccines provide long‑term, sustained protection against invasive cervical cancer, reducing risk by 79% over 18 years of follow‑up.
A large cohort study from Sweden followed 926,362 girls vaccinated with HPV vaccine between 2006–2023 for 18 years, showing a 79% reduction in invasive cervical cancer and evidence of sustained protection with no waning observed during follow‑up.
Sustained vaccine efficacy over decades supports continued HPV vaccination programs as a key strategy to eliminate cervical cancer worldwide.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- A multinational cross-sectional study on human papillomavirus and cervical cancer knowledge, vaccination attitudes, and risk factors in the Middle East
- Genomic features of cervical cancer
- Screening for Cervical Cancer
- Cervical cancer: Epidemiology, risk factors and screening
- AI approach outperformed human experts in identifying cervical precancer